Charles Schwab Investment Management Inc. Has $4.51 Million Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Charles Schwab Investment Management Inc. raised its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 0.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 427,477 shares of the company’s stock after acquiring an additional 3,530 shares during the period. Charles Schwab Investment Management Inc.’s holdings in ARS Pharmaceuticals were worth $4,510,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Compass Capital Corp MA ADV bought a new stake in ARS Pharmaceuticals during the 4th quarter worth approximately $106,000. Quarry LP acquired a new position in ARS Pharmaceuticals in the third quarter worth $174,000. Stifel Financial Corp acquired a new stake in shares of ARS Pharmaceuticals in the third quarter valued at $199,000. Intech Investment Management LLC acquired a new stake in shares of ARS Pharmaceuticals in the third quarter valued at $239,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of ARS Pharmaceuticals in the fourth quarter valued at about $175,000. Institutional investors own 68.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Raymond James increased their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 14th. William Blair reissued an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Oppenheimer started coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price objective for the company. Leerink Partners increased their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Finally, Scotiabank started coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 target price for the company. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $31.00.

ARS Pharmaceuticals Stock Performance

Shares of SPRY stock opened at $13.15 on Wednesday. The firm’s 50 day moving average price is $12.13 and its two-hundred day moving average price is $13.07. ARS Pharmaceuticals, Inc. has a 52-week low of $7.55 and a 52-week high of $18.51. The stock has a market cap of $1.28 billion, a PE ratio of -25.78 and a beta of 1.03.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its quarterly earnings results on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.56. The company had revenue of $86.58 million during the quarter, compared to the consensus estimate of $15.46 million. As a group, sell-side analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $11.10, for a total value of $555,000.00. Following the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,334,840.60. This trade represents a 19.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the transaction, the insider now directly owns 7,696 shares in the company, valued at approximately $107,744. This represents a 56.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 159,600 shares of company stock worth $1,866,516. Insiders own 40.10% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.